BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37182388)

  • 1. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis.
    Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H
    Thromb Res; 2023 Jun; 226():165-172. PubMed ID: 37182388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study.
    Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K;
    Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
    Yamakawa K; Ogura H; Fujimi S; Morikawa M; Ogawa Y; Mohri T; Nakamori Y; Inoue Y; Kuwagata Y; Tanaka H; Hamasaki T; Shimazu T
    Intensive Care Med; 2013 Apr; 39(4):644-52. PubMed ID: 23361628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Determining the Efficacy of Recombinant Human Thrombomodulin in the Treatment of Sepsis-Induced Disseminated Intravascular Coagulation.
    Kotake K; Hongo T; Tahira A; Niimi N; Haisa I; Kawakami Y
    Biol Pharm Bull; 2021 May; 44(5):605-610. PubMed ID: 33612566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis.
    Yamakawa K; Aihara M; Ogura H; Yuhara H; Hamasaki T; Shimazu T
    J Thromb Haemost; 2015 Apr; 13(4):508-19. PubMed ID: 25581687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
    Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
    J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.
    Yamakawa K; Fujimi S; Mohri T; Matsuda H; Nakamori Y; Hirose T; Tasaki O; Ogura H; Kuwagata Y; Hamasaki T; Shimazu T
    Crit Care; 2011; 15(3):R123. PubMed ID: 21569368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation.
    Yasuda N; Goto K; Ohchi Y; Abe T; Koga H; Kitano T
    J Crit Care; 2016 Dec; 36():29-34. PubMed ID: 27546744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of recombinant thrombomodulin administration on disseminated intravascular coagulation due to severe acute cholangitis (Recover-AC study).
    Ogura T; Eguchi T; Nakahara K; Kanno Y; Omoto S; Itonaga M; Kuroda T; Hakoda A; Ikeoka S; Takagi M; Okada A; Sato J; Morita R; Michikawa Y; Ito K; Koshita S; Takenaka M; Kitano M; Koizumi M; Higuchi K
    J Hepatobiliary Pancreat Sci; 2023 Feb; 30(2):221-228. PubMed ID: 34021720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study.
    Tagami T; Matsui H; Horiguchi H; Fushimi K; Yasunaga H
    J Thromb Haemost; 2015 Jan; 13(1):31-40. PubMed ID: 25393713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
    Yoshimura J; Yamakawa K; Ogura H; Umemura Y; Takahashi H; Morikawa M; Inoue Y; Fujimi S; Tanaka H; Hamasaki T; Shimazu T
    Crit Care; 2015 Mar; 19(1):78. PubMed ID: 25883031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study.
    Yoshihara M; Uno K; Tano S; Mayama M; Ukai M; Kondo S; Kokabu T; Kishigami Y; Oguchi H
    Crit Care; 2015 Oct; 19():369. PubMed ID: 26481315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and meta-analysis of recombinant human soluble thrombomodulin for the treatment of DIC associated with hematological malignancies.
    Kawano N; Fukatsu M; Yamakawa K; Seki Y; Wada H; Okamoto K; Ikezoe T
    Int J Hematol; 2024 Apr; 119(4):416-425. PubMed ID: 38270783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.
    Hagiwara A; Tanaka N; Uemura T; Matsuda W; Kimura A
    BMJ Open; 2016 Dec; 6(12):e012850. PubMed ID: 28039291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation.
    Hashimoto D; Chikamoto A; Miyanari N; Ohara C; Kuramoto M; Horino K; Ohshima H; Baba H
    J Surg Res; 2015 Aug; 197(2):405-11. PubMed ID: 25972310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Human Soluble Thrombomodulin Contributes to a Reduction In-Hospital Mortality of Acute Cholangitis with Disseminated Intravascular Coagulation: A Propensity Score Analyses of a Japanese Nationwide Database.
    Tarasawa K; Fujimori K; Fushimi K
    Tohoku J Exp Med; 2020 Sep; 252(1):53-61. PubMed ID: 32879147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human soluble thrombomodulin and short-term mortality of infection patients with DIC: a meta-analysis.
    Zhang C; Wang H; Yang H; Tong Z
    Am J Emerg Med; 2016 Sep; 34(9):1876-82. PubMed ID: 27452884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis.
    Ogawa Y; Yamakawa K; Ogura H; Kiguchi T; Mohri T; Nakamori Y; Kuwagata Y; Shimazu T; Hamasaki T; Fujimi S
    J Trauma Acute Care Surg; 2012 May; 72(5):1150-7. PubMed ID: 22673239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Recombinant Human Soluble Thrombomodulin on Coagulation-Related Variables in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Retrospective Observational Study.
    Mitaka C; Kawagoe I; Satoh D; Hayashida M
    Clin Appl Thromb Hemost; 2021; 27():10760296211050356. PubMed ID: 34859680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter clinical experience with recombinant soluble thrombomodulin for disseminated intravascular coagulation associated with severe acute cholecystitis.
    Ogura T; Eguchi T; Amano M; Sano T; Nishioka N; Miyano A; Tsujimae M; Tanimura H; Yamada T; Terashima Y; Okada A; Higuchi K
    Thromb Res; 2019 Apr; 176():74-78. PubMed ID: 30780007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.